Component
Plasma nattokinase-immunoreactive material
What a polyclonal anti-nattokinase ELISA detects in human serum. It may be intact enzyme, fragments, complexes or cross-reactive material; the assay does not distinguish them and no catalytic activity was measured.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
A polyclonal ELISA signal does not by itself distinguish intact catalytically active nattokinase from fragments, complexes or cross-reactive material.
Experimental context and source evidence
- duration
- Not stated here
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Human
- exposure
- Anti-nattokinase polyclonal capture ELISA
- limitations
- Recorded as an assay-scope limit, not as a negative finding. No study in the retrieved evidence immunocaptured the material and then measured catalytic activity on a substrate.
- organism
- Human
- plain_language
- A polyclonal ELISA signal does not by itself distinguish intact catalytically active nattokinase from fragments, complexes or cross-reactive material.
- primary_references
- A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. (2013) https://pubmed.ncbi.nlm.nih.gov/23709455/
- route
- In vivo, oral
- tissue
- Serum
Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 829–829
Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · Human · source_derived_draft · unverified_draft
A polyclonal ELISA signal does not by itself distinguish intact catalytically active nattokinase from fragments, complexes or cross-reactive material.
Complete structured claim and evidence
What acts on it
A single 2,000 FU oral NSK-SD dose produced anti-nattokinase immunoreactivity in serum that rose significantly from baseline between 2 and 24 h and peaked at about 13.3 +/- 2.5 h.
Experimental context and source evidence
- duration
- Single dose, sampling to 48 h
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Human (11 healthy adults, 5 male and 6 female, ages 21-65)
- exposure
- NSK-SD softgel, 2,000 FU, about 100 mg
- limitations
- No control group and a non-validated polyclonal rabbit anti-nattokinase capture ELISA. EFSA reviewed this study and noted the same limitations, adding that it did not assess the biological activity of nattokinase in blood. The authors themselves recommend that future work look separately for intact enzyme and for bioactive peptides.
- organism
- Human (11 healthy adults, 5 male and 6 female, ages 21-65)
- plain_language
- A single 2,000 FU oral NSK-SD dose produced anti-nattokinase immunoreactivity in serum that rose significantly from baseline between 2 and 24 h and peaked at about 13.3 +/- 2.5 h.
- primary_references
- A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. (2013) https://pubmed.ncbi.nlm.nih.gov/23709455/
- route
- In vivo, oral
- tissue
- Serum
Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 818–818
Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · Human (11 healthy adults, 5 male and 6 female, ages 21-65) · source_derived_draft · unverified_draft
A single 2,000 FU oral NSK-SD dose produced anti-nattokinase immunoreactivity in serum that rose significantly from baseline between 2 and 24 h and peaked at about 13.3 +/- 2.5 h.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.